INTRODUCTION {#s1}
============

Non-small cell lung cancer (NSCLC) accounts for 80%--85% of all lung cancer cases.\[[@R1]\] The majority of patients present with advanced disease. Although some improvements have been made, the five-year survival rate of NSCLC (16.6%) is still lower than many other leading cancers, such as the colon (64.2%), breast (89.2%) and prostate (99.2%) cancer. Recent studies suggested that some tumors have distinct molecular characteristics that allow them to be further classified into subsets of disease beyond the histologic level.\[[@R2]\] By focusing on cancer-specific molecular changes, targeted cancer therapies may be more effective than other traditional treatments, such as chemotherapy and radiotherapy, and less harmful to normal cells.\[[@R3]\]

Immune evasion is now recognized as a key feature of cancer progression.\[[@R4]\] Interactions among subsets of immune cells through costimulatory ligands and their receptors are essential for the initiation of an immune response. The lack of CD80 and CD86 expression on tumor cells is one of the mechanisms of the immune evasion of tumor cells.\[[@R5], [@R6]\] B7-H1 (PD-L1) and B7-H3, two novel members of B7/CD28 superfamily, complicate the immune response by adjusting the effects of costimulation on T-cells.\[[@R7], [@R8]\] B7-H1 is abundant on tumor cell lines and tumor tissues, and cancer cells expressing B7-H1 have been shown to increase apoptosis of antigen-specific human T-cell clones \[[@R4]\] and to inhibit CD4^+^ and CD8^+^ T-cell activation *in vitro*.\[[@R9]\] In addition, tumor cells transfected with B7-H1 were shown to grow even after adoptive T-cell immunotherapy, whereas blockade of PD-1/B7-H1 inhibited tumorigenesis *in vivo*.\[[@R10], [@R11]\] B7-H3, whose receptors have not yet been identified, is believed to be involved in both costimulatory and co-inhibitory pathways.\[[@R12]\] B7-H3 has been regarded as a positive regulation molecule as it was shown to stimulate CD4^+^ and CD8^+^T cells to increase the activity of cytotoxic T lymphocytes.\[[@R13]\] However, further studies revealed that B7-H3 could also inhibit the proliferation of T cells *in vitro* and reduce the secretion of interferon-γ (IFN-γ), tumor necrosis factor-α, granulocyte macrophage colony-stimulating factor, and other cytokines.

Prolonged survival has associated with a large number of tumor-infiltrating lymphocytes (TILs) in cancer, measured by the infiltration of CD3^+^ T cells \[[@R14]\], CD8^+^ T cells \[[@R15]\] or CD57^+^ NK cells.\[[@R16]\] Recent studies found that cytotoxic granule-associated RNA binding protein (TIA-1) was a good marker to detect cytotoxic cells, which coded for an integral membrane protein in cytotoxic granules, mainly in cytotoxic CD8^+^ T cells (CTLs, regardless of their activation state) and NK cells. \[[@R17]\] Tumor cells, which express a relatively restricted repertoire of chemokine and chemokine receptors, utilize and manipulate the chemokine system in a manner that benefits both local tumor growth and distant dissemination. Among the 19 chemokine receptors, CXCR4 is the receptor most widely expressed by malignant tumors and whose role in tumor biology is most thoroughly studied.\[[@R18]\] The functional expression of CXCR4 induces lung cancer cell migration and adhesion to stromal cells when binding to its unique ligand stromal cell-derived factor-1 (SDF-1), which in turn provides growth- and drug-resistance signals to tumor cells. CXCR4 antagonists, such as Plerixafor (AMD3100) and T140 analogues (TN14003/BKT140), can disrupt CXCR4-mediated tumor cell adhesion to stromal cells and sensitize lung cancer cells to cytotoxic drugs.\[[@R19]\] Study in head and neck squamous cell carcinoma showed that IFN-γ could also significantly reduce the expression of CXCR4.\[[@R20]\]

Although B7-H1 and B7-H3 was reported to express in cancer, their expression in NSCLC has not been fully characterized. Therefore, we sought to investigate their expression in NSCLC samples. In the present study, we evaluated B7-H1 and B7-H3 expression in NSCLC tissues via immunohistochemical analysis to determine the relationship between their expression and other clinicopathologic variables and their value in prognosis. We also assessed the association between B7-H1 and B7-H3 expression on tumor cells and TIA-1 and IFN-γ expression on TILs. The biological effects and their mechanisms of tumor-associated B7-H3 on T-cell proliferation and tumor cell migration were also explored.

RESULTS {#s2}
=======

B7-H1 and B7-H3 expression in NSCLC tissues {#s2_1}
-------------------------------------------

Staining for B7-H1 was observed in the cell cytoplasm and membrane in both cancerous and noncancerous cells. However, staining for B7-H3 was only found in cancerous cells. B7-H1 was more commonly expressed in NSCLC tissues (93/128 cases, 72.7%) than in adjacent normal tissues (12/128 cases, 30%; p\< 0.01; Figure [1](#F1){ref-type="fig"}). Similarly, B7-H3 was more commonly expressed in NSCLC tissues (89/128 cases, 69.5%) than in adjacent tissues (0/128 cases, 0%; p\< 0.01; Figure [1](#F1){ref-type="fig"}).

![Immunohistochemical staining showing B7-H1 and B7-H3 expression in NSCLC and normal lung tissues (original magnification ×100)\
(A) Negative cytoplasmic expression of B7-H1 (B) Positive cytoplasmic expression of B7-H1 (C) Negative cytoplasmic expression of B7-H3 (D) Positive cytoplasmic expression of B7-H3.](oncotarget-06-3452-g001){#F1}

Relationship between B7-H1 and B7-H3 expression and clinicopathologic parameters {#s2_2}
--------------------------------------------------------------------------------

The relationship between tumor cell B7-H1/B7-H3 expression and clinicopathologic parameters was shown in (Table [1](#T1){ref-type="table"}) B7-H1/B7-H3 expression in NSCLC tissue samples was associated with lymph node metastasis and advanced TNM stage (p\<0.05 for both). Expression of either protein was not associated with sex, histopathologic type, or histologic grade. We also found a positive correlation between B7-H1 expression and B7-H3 expression in NSCLC tissue samples (p\<0.05). Co-expression of B7-H1 and B7-H3 was observed in 68/128 (53.1%) NSCLC tissue samples but not in adjacent tissues. Furthermore, B7-H1 and B7-H3 co-expression was much more common in patients with lymph node metastasis (72.9%) than in those without lymph node metastasis (29.3%; p\<0.01). The proportion of samples in which B7-H1 and B7-H3 were co-expressed increased as TNM stage (I, II, or III) increased (26.7%, 53.5%, and 82.5%, respectively; p\<0.01). The co-expression of B7-H1 and B7-H3 was not significantly associated with age, sex, histopathologic type, histologic grade, and tumor size. (Table [1](#T1){ref-type="table"})

###### Relationship between clinicopathologic parameters and B7-H1, B7-H3, TIA-1, IFN-γ, and CXCR4 expression in NSCLC (n=128)

  Clinicopathologic parameters   No. of patients   B7-H1 expression   p value   B7-H3 expression                              p value   TIA-1^+^ expression   p value                                         IFN-γ^+^ expression   p value   CXCR4 expression                                p value                                                                  
  ------------------------------ ----------------- ------------------ --------- --------------------------------------------- --------- --------------------- ----------------------------------------------- --------------------- --------- ----------------------------------------------- --------- ---- ----------------------------------------------- ---- ---- ---------------------------------------------
  **Age at diagnosis (years)**                                                                                                                                                                                                                                                                                                                                         
    ≤60                          51                17                 34        **0.22**                                      10        41                    **0.03[\*](#tfn_001){ref-type="table-fn"}**     32                    19        **0.06**                                        31        20   **0.53**                                        16   35   **0.02[\*](#tfn_001){ref-type="table-fn"}**
    \>60                         77                18                 59                                                      29        48                                                                    35                    42                                                        51        26                                                   41   36   
  **Sex**                                                                                                                                                                                                                                                                                                                                                              
    Male                         91                21                 70        **0.09**                                      30        61                    **0.34**                                        42                    49        **0.03[\*](#tfn_001){ref-type="table-fn"}**     57        34   **0.60**                                        42   49   **0.56**
    Female                       37                14                 23                                                      9         28                                                                    25                    12                                                        25        12                                                   15   22   
  **Histopathologic type**                                                                                                                                                                                                                                                                                                                                             
    Squamous cell carcinoma      61                16                 45        **0.79**                                      23        38                    **0.09**                                        26                    35        **0.04[\*](#tfn_001){ref-type="table-fn"}**     37        24   **0.45**                                        30   31   **0.31**
    Adenocarcinoma               67                19                 48                                                      16        51                                                                    41                    26                                                        45        22                                                   27   40   
  **Differentiation**                                                                                                                                                                                                                                                                                                                                                  
    Poor                         45                10                 35        **0.34**                                      12        33                    **0.73**                                        23                    22        **0.49**                                        32        13   **0.25**                                        18   27   **0.54**
    Moderate                     22                7                  15                                                      6         16                                                                    14                    8                                                         13        9                                                    10   12   
    Well                         61                18                 43                                                      21        40                                                                    30                    31                                                        37        24                                                   29   32   
  **Tumor size**                                                                                                                                                                                                                                                                                                                                                       
    ≤3cm                         38                13                 25        **0.04[\*](#tfn_001){ref-type="table-fn"}**   12        26                    **0.59**                                        18                    20        **0.34**                                        24        14   **0.93**                                        15   23   **0.63**
    \>3cm≤7cm                    65                20                 45                                                      21        44                                                                    34                    31                                                        42        23                                                   31   34   
    \>7cm                        25                2                  23                                                      6         19                                                                    15                    10                                                        16        9                                                    11   14   
  **Lymph node metastasis**                                                                                                                                                                                                                                                                                                                                            
    N~0~                         58                21                 37        **0.04[\*](#tfn_001){ref-type="table-fn"}**   31        27                    **\<0.01[\*](#tfn_001){ref-type="table-fn"}**   23                    35        **0.01[\*](#tfn_001){ref-type="table-fn"}**     31        27   **0.02[\*](#tfn_001){ref-type="table-fn"}**     30   28   **0.14**
    N~1~                         70                14                 56                                                      8         62                                                                    44                    26                                                        51        19                                                   27   43   
  **TNM stage**                                                                                                                                                                                                                                                                                                                                                        
    I                            45                15                 30        **0.04[\*](#tfn_001){ref-type="table-fn"}**   28        17                    **\<0.01[\*](#tfn_001){ref-type="table-fn"}**   12                    33        **\<0.01[\*](#tfn_001){ref-type="table-fn"}**   23        22   **\<0.01[\*](#tfn_001){ref-type="table-fn"}**   23   22   **0.01[\*](#tfn_001){ref-type="table-fn"}**
    II                           43                15                 28                                                      8         35                                                                    20                    23                                                        25        18                                                   26   17   
    III                          40                5                  35                                                      3         37                                                                    35                    5                                                         34        6                                                    8    32   

p\<0.05

Relationship between TIA-1, IFN-γ, and CXCR4 expression and clinicopathologic parameters {#s2_3}
----------------------------------------------------------------------------------------

The rates of TIA-1^+^ and IFN-γ^+^ cell high infiltration (47.7% and 35.9%, respectively) in NSCLC tissues were significantly higher than those in adjacent tissues (p\<0.01, respectively). The infiltration levels of TIA-1^+^ and IFN-γ^+^ cells in NSCLC tissues decreased in the presence of lymph node metastasis and as the TNM pathologic stage increased (p\<0.05, respectively), but the rate of TIA-1^+^ cell high infiltration in squamous cell carcinomas (57.4%) was obviously higher than that in adenocarcinomas (38.8%; p=0.04). The overexpression (55.5%) of CXCR4 in NSCLC tissues was significantly higher than that in the adjacent tissues (p\<0.01). CXCR4 was only minimally expressed in the adjacent tissues. CXCR4 expression increased as the TNM pathologic stage increased (p=0.01). (Table [1](#T1){ref-type="table"})

In NSCLC tissues, B7-H3 expression was positively correlated with CXCR4 expression (r=0.36; p\<0.01). The high infiltration rate of TIA-1^+^ cells was positively associated with the high infiltration rate of IFN-γ^+^ cells (r=0.28; p\<0.01).

Relationship between B7-H1 and B7-H3 expression and OS {#s2_4}
------------------------------------------------------

At the time of the final follow-up, 85 of 128 patients had died; of the remaining 43, 42 were alive and 1 was lost to follow-up. Patients whose tumors were positive for B7-H1 had shorter OS times than those whose tumors were negative for B7-H1 (28.7 months vs 60.6 months; p\<0.01). Other prognostic factors were also shown to negatively affect OS, including B7-H3 (25.0 months vs 60.6 months; p\<0.01) and CXCR4 expression (28.7 months vs 40.7 months; p= 0.08). Patients whose tumors were negative for both B7-H1 and B7-H3 had the best prognosis (60.6 months), whereas those with tumors in which both B7-H1 and B7-H3 were expressed had the poorest prognosis (22.7 months). NSCLC patients with high infiltration rates of TIA-1^+^ or IFN-γ^+^ cells had a better prognosis than those with low infiltration rates.(Table [2](#T2){ref-type="table"}) After adjusting for sex, tumor differentiation, tumor size, lymph node metastasis, TNM stage, and expression of B7-H1, B7-H3, TIA-1^+^, IFN-γ^+^, and CXCR4, patients whose tumors were positive for B7-H1 (HR, 1.90; 95% CI, 1.09-3.30; p=0.02) or B7-H3 (HR, 2.26; 95% CI, 1.21-4.23; p=0.01) were at an increased risk of death. (Table [3](#T3){ref-type="table"}) In addition, patients who were male, had advanced TNM stage disease, or had low infiltration of TIA-1^+^ in their tumors were also at an increased risk of death (p\<0.05 for both).

###### Correlation between molecular markers and median OS in NSCLC patients (univariate analysis)

  Molecular markers     Cases (n)   MST (months)   Log-rank p value
  --------------------- ----------- -------------- -------------------------------------------
  **B7-H1**                                        
    negative            35          60.6           \<0.01[\*](#tfn_002){ref-type="table-fn"}
    positive            93          28.7           
  **B7-H3**                                        
    negative            39          60.6           \<0.01[\*](#tfn_002){ref-type="table-fn"}
    positive            89          25.0           
  **TIA-1^+^**                                     
    low infiltration    67          20.5           \<0.01[\*](#tfn_002){ref-type="table-fn"}
    high infiltration   61          59.2           
  **IFN-γ^+^**                                     
    low infiltration    82          28.7           0.02[\*](#tfn_002){ref-type="table-fn"}
    high infiltration   46          44.7           
  **CXCR4**                                        
    negative            57          40.7           0.08
    positive            71          28.7           
  **B7-H1/B7-H3**                                  
    B7-H1−/B7-H3−       14          60.6           \<0.01[\*](#tfn_002){ref-type="table-fn"}
    B7-H1−/B7-H3+       21          37.1           
    B7-H1+/B7-H3−       25          49.5           
    B7-H1+/B7-H3+       68          22.7           

p\<0.05; MST, median survival time

###### Correlation between clinicopathologic parameters and median OS in NSCLC patients (multivariate analysis)

  Clinicopathologic parameters   HR     95.0% CI    p value
  ------------------------------ ------ ----------- -------------------------------------------
  **Sex**                        0.52   0.30-0.90   0.02[\*](#tfn_003){ref-type="table-fn"}
  **Tumor differentiation**      0.74   0.52-1.06   0.10
  **Tumor size**                 0.85   0.63-1.16   0.31
  **Lymph node metastasis**      0.92   0.42-2.01   0.84
  **TNM stage**                  1.82   1.05-3.16   0.03[\*](#tfn_003){ref-type="table-fn"}
  **B7-H1**                      1.90   1.09-3.30   0.02[\*](#tfn_003){ref-type="table-fn"}
  **B7-H3**                      2.26   1.21-4.23   0.01[\*](#tfn_003){ref-type="table-fn"}
  **TIA-1^+^**                   0.32   0.16-0.63   \<0.01[\*](#tfn_003){ref-type="table-fn"}
  **IFN-γ^+^**                   1.45   0.78-2.67   0.24
  **CXCR4**                      0.86   0.53-1.38   0.52

p\<0.05; HR, hazard ratio; CI, confidence interval.

B7-H3 expression on lung cancer cell lines and its association with metastasis {#s2_5}
------------------------------------------------------------------------------

B7-H3 was highly expressed on lung cancer H1299 cells. The B7-H3 gene silencing on H1299 cells promoted the proliferation of T-cells and stimulated these cells to secrete IFN-γ with the costimulation by anti-CD3 mAb and anti-CD28 mAb *in vitro* (p\<0.05). (Figure [2](#F2){ref-type="fig"}) It also showed that IFN-γ reduced CXCR4 expression on H1299 cells by both flow cytometry and RT¬-PCR. (Figure [3A and B](#F3){ref-type="fig"}) Like AMD3100 (a CXCR4 antagonist), IFN-γ significantly inhibited the migration capacity of H1299 cells stimulated by CXCL12 (p\<0.01) (Figure [3C](#F3){ref-type="fig"}). *In vitro* scratch assay revealed that the knockdown of B7-H3 on H1299 cells slowed the migration of cells toward the scratch. (Figure [4](#F4){ref-type="fig"}) However, when B7-H3 gene was transfected to B7-H3 low expressed lung cancer SPC-A1 cells, we found a significantly inhibition of proliferation and IFN-γ secretion of T-cells (p\<0.05). (Figure [2](#F2){ref-type="fig"})

![Effects of B7-H3 expression on T-cell proliferation and IFN-γ secretion (1) B7-H3 expression of on cell membrane of H1299\
(A) and SPC-A1 (B) cells (2) T-cell proliferation (C) and IFN-γ secretion (D) stimulated by B7-H3 silencing or transfected cells (\*p\<0.05; \*\*p\<0.001) H1299-NC, vector-transfected H1299 cells; H1299-KD, B7-H3 knockdown H1299 cells; SPC-A1-mock, vector-transfected SPC-A1 cells; SPC-A1-B7-H3, B7-H3-transfected SPC-A1 cells. Experiments were done in triplicate and average ± SE displayed.](oncotarget-06-3452-g002){#F2}

![H1299 cell migration induced by IFN-γ after 72 hours\
(A) CXCR4 expression by flow cytometry; (B) CXCR4 expression by RT-PCR; (C) Migration ability of H1299 cells before and after IFN-γ stimulation (\*p\<0.001, compared with all other groups; ^\#^p\<0.01, compared with the IFN-γ+CXCL12 group) Experiments were done in triplicate and average ± SE displayed.](oncotarget-06-3452-g003){#F3}

![Migration capacity of H1299-KD and H1299-NC cells H1299-NC cells covered with scratches after 24 hours of incubation, whereas the same phenomena were not observed on H1299-KD cells\
H1299-NC, vector-transfected H1299 cells; H1299-KD, B7-H3 knockdown H1299 cells. Experiments were done in triplicate.](oncotarget-06-3452-g004){#F4}

DISCUSSION {#s3}
==========

Our results revealed cytoplasmic and membrane expression of B7-H1 and B7-H3 in surgically resected NSCLC specimens. The expression patterns of these molecules were consistent with those reported in previous studies that examined their expression in human tumor tissue.\[[@R4], [@R9], [@R10], [@R21]\] B7-H1 and B7-H3 were more likely to be expressed in NSCLC cells than in normal lung tissues, and B7-H1/B7-H3 expression was associated with decreased OS in patients with NSCLC. Thus, B7-H1/B7-H3 expression in NSCLC tissues could be a useful independent predictor of prognosis. Biological studies showed that B7-H3 was a negative regulatory molecule, as it inhibited T-cell proliferation and promoted tumor cell migration.

Accumulating evidence \[[@R22]\] has indicated that B7 family molecules are widely expressed in NSCLC and that their interactions with corresponding receptors are directly related to T-cell engagement of antigens. Previous studies revealed low expression of B7-H1 and high expression of B7-H3 in NSCLC. B7-H1 and B7-H3 expression was associated with a decreased number of TILs.\[[@R23]-[@R25]\] However, a recent study by Boland *et al*. did not reveal an association with B7-H1 or B7-H3 expression and the number of TILs in squamous cell lung carcinoma. Our study showed that B7-H1 and B7-H3 expression and the number of infiltrating TIA-1^+^ and IFN-γ^+^ cells in NSCLC tissues were significantly higher than those in the adjacent tissues. Statistical analysis revealed that high B7-H1 or B7-H3 expression was associated with lymph node metastasis (p\<0.05) and TNM stage (p\<0.05).

Only one study showed B7-H1 expression in NSCLC positivity correlated with survival shorter than 3 years after lobectomy\[[@R23], [@R26], [@R27]\], and the findings of studies of B7-H3 and survival were controversial. Xu *et al*. \[[@R24]\] reported that low B7-H3 expression was associated with poor prognosis in NSCLC, whereas, Bonald *et al*.\[[@R27]\] found no association between B7-H3 expression and poorer survival in squamous cell carcinoma of the lung. In this study, we found that B7-H1, B7-H3, and TIA-1 expression remained significant prognostic factors after adjusting for other prognostic factors in a multivariate Cox proportional hazards regression model. It showed that B7-H1 and B7-H3 could repress the antitumor immune response in NSCLC by inhibiting the infiltration of cells that express TIA-1 and IFN-γ. Thus, our results indicate that B7-H1 and B7-H3 expression is an independent predictor of poor prognosis in patients with NSCLC. The interference of the signal pathways of these negative regulatory molecules might be a new strategy for treating NSCLC. Our results indicate that B7-H3 has inhibitory effects on the immune system; however, the real function of B7-H3 in human NSCLC could be more complicated.

The mechanisms regulating B7-H3 expression on tumor cells are not well known. Previous studies suggested that the cytokine microenvironment induced the expression of B7-H1 on tumor cells.\[[@R23], [@R28]\] In addition, T-cells or natural killer cells that infiltrated into tumor tissue were shown to secrete IFN-γ and some other cytokines. In the current study, decreasing IFN-γ prompted CXCR4 expression on cancer cells, which could help tumor cells escape from immunity. These results suggest that B7-H3 may be involved in the development of human NSCLC.

One limitation of our study was the relatively small sample, which could lead to an overestimation of the magnitude of relationships between variables. Our patients had stage I-III disease and received various kinds of therapy, which may have introduced treatment bias. Nonetheless, our findings suggest that B7-H1 and B7-H3 play an important role in tumor metastasis and thus could be applied as prognostic markers and/or targets for NSCLC therapy. Further investigations are necessary to clarify and understand the role of B7-H1 and B7-H3 in patients with NSCLC.

MATERIALS AND METHODS {#s4}
=====================

Tissue samples {#s4_1}
--------------

Primary tumor samples and clinical data were obtained from 128 patients with NSCLC who underwent surgery without any preoperative therapy (91 men and 37 women; median age at diagnosis, 62.5 years) between March 2005 and October 2007 at the First Affiliated Hospital of Soochow University and Shanghai Renji Hospital in China. NSCLC stage was classified according to the AJCC tumor-node-metastasis (TNM) staging system (2002 version).\[[@R29]\] Cell differentiation was determined using the World Health Organization (WHO) classification (2000 revision).\[[@R30]\] Data on patients\' age, sex, tumor location, histopathologic type, histologic grade, tumor size, lymph node invasion, and tumor stage were extracted from medical records. The median follow-up time was 53.3 months (range, 40.3-74.0 months), and the most recent follow-up correspondence was initiated on March 31, 2011. The study was conducted after informed consent was obtained from all patients and approval from an independent research ethics committee.

Cell lines {#s4_2}
----------

Lung cancer cell lines H1299 (HLA-A\*0201^−^) and SPC-A1 (HLA-A\*0201^−^) were form Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and maintained in RPMI-1640 medium supplemented with 10% fetal calf serum.

Immunohistochemical analysis {#s4_3}
----------------------------

Immunostaining was performed using the EliVision plus kit (Maixin-Bio, Fuzhou, China). Formalin-fixed, paraffin-embedded tissue blocks were sectioned to 3 μm and mounted on charged glass slides (Fisher Scientific, Pittsburgh, PA). Antigen retrieval was done in a citrate buffer \[20 mmol/L (pH 6.0)\] at 120°C for 10 minutes. Endogenous peroxidase activity was blocked with 3.0% hydrogen peroxide for 10 minutes. Mouse anti-human B7-H1 monoclonal antibody (mAb; diluted 1:100; Clone 2H11) \[[@R31]\] and mouse anti-human B7-H3 mAb (diluted 1:100; Clone 4H7) \[[@R32]\] were used as the primary antibodies, and mouse immunoglobulin G was used as the negative control. Mouse anti-human TIA-1 mAb, mouse anti-human IFN-γ mAb, and mouse anti-human CXCR4 mAb were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and used according to the manufacturer\'s instructions. For visualization, the sections were incubated with 3, 3-diaminobenzidine solution and counterstained with hematoxylin.

Evaluation of immunostaining {#s4_4}
----------------------------

Histologic analysis was performed by two investigators simultaneously without knowledge of the patients\' clinical characteristics. B7-H1 and B7-H3 expression was measured as the percentage of tumor cells displaying immunoreactivity in the cytoplasm or on the membrane, which was determined by counting the number of B7-H1- or B7-H3-stained tumor cells out of 1,000 tumor cells in each section. Cells were counted at 400× magnification in at least 10 fields in randomly selected tumor areas. Staining was evaluated using a semiquantitative assay previously described by Remmele *et al*.\[[@R33]\] The immunoreactive score was calculated by multiplying the staining intensity. The percentage of cells with positive staining was scored as follows: 0 = no staining, 1 = weak staining, 2 = moderate staining, and 3 = strong staining. The percentage of positively stained cells was scored as follows: 0 = no staining, 1 = 1%-10% of cells, 2 = 11%-50% of cells, and 3 = more than 50% of cells stained. The total score per sample therefore ranged from 0 to 9 whereby 0 indicated no staining (e.g., negative results), 1 indicated weak staining, 2 or 3 indicated moderate staining, and more than 3 indicated strong staining. In the final analysis, samples with no staining or weak staining were considered to have negative expression, and samples with moderate or strong staining were considered to have positive expression.

Whole areas of each section were surveyed microscopically at 40× magnification, and cells counts were performed at 400× magnification in at least five fields in randomly selected tumor areas. The density of tumoral lymphoid infiltrates was quantified by counting the small round lymphocytes distributed within the tumor epithelium and the peritumoral stroma. TIA-1-expressing TILs were scored as follows: 0 = no staining, 1 = 1-25 cells stained, 2 = 26-50 cells stained, and 3 = 51 or more cells stained. IFN-γ-expressing TILs were scored as follows: 0 = no staining, 1 = 1-5 cells stained, 2 = 6-19 cells stained, and 3 = 20 or more cells stained. Scores from 0 to 1 were considered low infiltration, whereas scores from 2 to 3 were defined as high infiltration.\[[@R34]\]

Reverse transcriptase polymerase chain reaction {#s4_5}
-----------------------------------------------

The tumor cells were harvested and lysed in TRIzol reagent (Invitrogen, CA). First-strand cDNA was prepared using random primers and following the manufacturer\'s instructions for the SuperScript III First-Strand Synthesis kit (Invitrogen, CA). Synthesis of cDNA was controlled by performing reverse transcriptase polymerase chain reaction (RT-PCR) using glyceraldehyde 3-phosphate dehydrogenase primers. RT-PCR with the primers 5′-TACTCGAAGCCCAGCATGACC-3′ (forward primer) and 5′-CCACCAGCAGTGCAATGAGAC-3′ (reverse primer) specific for human B7-H3, the primers 5′-CTAATTATTCGGTAACTGACTTGA-3′ (forward primer) and 5′-ACAGTTCAGCCATCACTTGGA-3′ (reverse primer) specific for human IFN-γ, and the primers 5′-GTCGTGGAGTCTACTGGCGTCTT-3′ (forward primer), 5′-CAGTCTTCTGAGTGGCAGTGATGG-3′ (reverse primer) specific for human glyceraldehyde 3-phosphate dehydrogenase was performed using TaKaRa LA Taq enzyme (Takara, Shiga, Japan). Cycle conditions were 94°C for 30 seconds, 58°C for 30 seconds, and 72°C for 30 seconds for 35 cycles.

Flow cytometry {#s4_6}
--------------

Cell surface expression was determined via immunofluorescence staining and flow cytometry with the Coulter Epics XL flow cytometer with EXPO32 software (Beckman Coulter, CA). The cells were incubated with anti-B7-H1 mAb (2H11) or anti-B7-H3 mAb (4H7) for 30 minutes at room temperature. After being washed thoroughly with phosphate-buffered saline (PBS), the cells were stained with phycoerythrin-conjugated goat anti-mouse antibodies (Immunotech, Marseille, France) for 30 minutes at 4°C. Non-specific staining was determined using isotype control antibodies.

Transfection {#s4_7}
------------

SPC-A1 cells were transfected with the pIRES2-EGFP plasmid containing the full-length human B7-H3 gene (SPC-A1-B7-H3) or with the wild-type pIRES2-EGFP plasmid (SPC-A1-Mock) and selected on the basis of G418 resistance. B7-H3 knockdown (H1299-KD) and vector control (H1299-NC) H1299 cells were transfected with the corresponding pGPU6/GFP/Neo plasmids (GenePharma, Shanghai, China), and the expression of surface molecules was confirmed by flow cytometry using an anti-B7-H3 mAb (4H7).

*In vitro* analysis of T-cell responses {#s4_8}
---------------------------------------

For T-cell proliferation assays, 96-well flat-bottom plates were coated with 1 μg/ml agonist anti-CD3 and 5 μg/ml anti-CD28 mAb (Immunotech, Marseille, France) in PBS at 4°C overnight. Either mitomycin-treated tumor cells or medium alone was added to the plates cocultured with 1×10^5^ purified T-cells obtained from peripheral blood mononuclear cells (HLA-A\*0201^−^) at an effector-to-target ratio of 1:10, 1:20, and 1:100. Then, T-cells were incubated for 72 hours and pulsed with 1 μCi of \[^3^H\] thymidine. Sandwich enzyme-linked immunosorbent assay for human IFN-γ was performed according to the manufacturer\'s instructions (R&D Systems, Minneapolis, MN).

Migration assays {#s4_9}
----------------

Transwell migration assays were conducted on H1299 cells with natural B7-H3 gene expression. Tumor cells were pretreated with IFN-γ (10 ng/ml) or AMD3100 (10 μg/ml) for 24 hours. Transwell chambers (8-μM pore) were coated with 10 μg/mL fibronectin (Sigma-Aldrich, St. Louis, MO) and incubated overnight at 4°C, washed in PBS, and rehydrated with serum-free media for 30 minutes at 37°C. The media were removed, and cells (1×10^5^/chamber) were added to upper chambers with 100 ng/ml CXCL12 in lower chambers as a chemoattractant. IFN-γ was chosen as a control. The chambers were incubated for 20 hours at 37°C and 5% CO~2~. Migrated cells on the underside of the filter were fixed in 10% ethanol for 20 minutes prior to staining with 4,6-diamidino-2-phenylindole (Sigma-Aldrich, St. Louis, MO) for 10 minutes at room temperature. Membranes were mounted on glass slides, and cells were enumerated using flow cytometry (Beckman Coulter, Brea, CA) to analyze multiple fluorescent micrographs. Results from three independent experiments with three replicates per experiment were pooled.

Scratch-wound migration assays were conducted on H1299 cells after B7-H3 gene knockdown. When cell monolayers reached 90% confluence, a scratch wound was made using a pipette tip. The closure of the wound was measured after 20 hours.

Statistical analysis {#s4_10}
--------------------

Comparisons between unpaired groups were made using the Mann-Whitney *U* test. Correlations between the parameters were evaluated with Spearman\'s rank correlation test. The overall survival (OS) times of patients whose specimens did or did not have B7-H1/B7-H3 expression were compared using the Kaplan-Meier method of survival analysis and the log-rank test. For all patients, survival time was calculated from the date of pathologic diagnosis of cancer to the date of death or last follow-up. The data from patients who were alive at the last day of follow-up were censored. The median follow-up time was calculated using only censored data. The median survival time was also calculated. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using univariate and multivariate Cox proportional hazard models. All statistical testing was conducted using SPSS software, version 20.0 (Chicago, IL). p values were two-sided, and p\<0.05 was considered statistically significant.
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